Posted by Gary Schwitzer in Drug industry, Health care journalism
A new edition of the ProPublica “Dollars for Docs” project she wrote:
“…biopharmaceutical companies are not just gatherers of clinical data, they are disseminators of that data, as well. After all, that information can’t help one patient if it doesn’t get to the physician first.”
Oh, this is going to be a fun exchange to follow.
Better than a competing piece by Reuters but still a little short on some details about this asthma drug study.
An adequate summary of this asthma drug trial’s design doesn’t make up for the overly optimistic tone about the drug’s future. A New York Times story was better.
This story focuses on a family that may have a rare genetic mutation that increases their risk of heart disease. Unfortunately, the “rare” part wasn’t mentioned until 1,600 words into this 2,100 word story.
We will not display your name or e-mail address on the site, nor will we share youre-mail address with any third parties.
For site updates and news from Gary, find us on Twitter:
HealthNewsReview: @HealthNewsRevu
Gary Schwitzer: @garyschwitzer
Copyright © 2013 Health News Review
Dr Joe posted on September 12, 2011 at 9:43 pm
Funny how the information does not need to get to physicians when the finding is negative about drugs.